Health Kick Podcast: Neurizon gears up for big year in tackling ALS

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode Tim chats with Dr Michael Thurn, Managing Director at Neurizon Therapeuctics (ASX:NUZ).

Neurizon was recently granted orphan medicinal product designation (OMPD) by the European Medicines Agency (EMA) for its lead drug candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS).

The company has also filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for NUZ-001, a pivotal step toward initiating a Phase 2/3 clinical trial under the HEALEY ALS Platform Trial framework.

The FDA now has 30 days to review the IND application, which, if approved, will enable the start of patient enrolment.

Like to tune in through another app? Just search for Health Kick Podcast with Tim Boreham and subscribe!

This podcast was developed in collaboration with Neurizon Therapeuctics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.